Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF )
Clinical Pharmacology & Therapeutics · 03.11.2026
DOI: 10.1002/cpt.70540 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 03.11.2026. Verfasst von Hossam Sharaf und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Early adjunctive therapies may improve decongestion and symptoms in acute heart failure. This trial compared dapagliflozin with acetazolamide when initiated early, focusing on dyspnea relief as the primary outcome and decongestive, diuretic, natriuretic, and safety outcomes. In this randomized, active‐controlled trial, 108 adults hospitalized with acute heart failure, dyspnea, and objective evidence of congestion requiring intravenous loop diuretics were randomized to receive dapagliflozin 10 mg ( N = 55) or acetazolamide 500 mg ( N = 53) once daily for 3 days alongside standard care. The primary endpoint was the between‐group difference in 72‐hour dyspnea visual analog scale area under the curve. Secondary endpoints included successful decongestion within 3 days, diuretic and natriuretic responses, the relative change in N‐terminal pro‐B‐type natriuretic peptide levels from baseline to day 3, and safety. Acetazolamide produced a significantly lower 72‐hour dyspnea area under the curve than dapagliflozin (2647.9 ± 1213.8 vs. 2988.7 ± 1196.7 mm × hour; P = 0.048). It increased cumulative urine output over 72 hours (12,200 vs. 10,000 mL; P = 0.019) and total natriuresis over 48 hours (824.7 vs. 547.9 mmol; P = 0.001). Dapagliflozin achieved a larger reduction in N‐terminal pro‐B‐type natriuretic peptide at 72 hours (−34.2% vs. −25.0%; P = 0.003). Safety events were infrequent and similar. In conclusion, acetazolamide provided greater dyspnea relief, diuresis, and natriuresis, whereas dapagliflozin produced a larger short‐term reduction in N‐terminal pro‐B‐type natriuretic peptide. Further studies are needed to validate these findings. Trial registration: https://clinicaltrials.gov/study/NCT06783166 .
Autor:innen und Institutionen
- Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
- Department of Pharmacy Practice, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt.
- Cardiology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
ORCID-Profile: Hossam Sharaf, Moheb Wadie, Noha O Mansour, Mohamed E E Shams
Zitieren
APA
Sharaf, H., Wadie, M., Mansour, N. O., & Shams, M. E. E. (2026). Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF ). Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70540
Vancouver
Sharaf H, Wadie M, Mansour NO, Shams MEE. Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF ). Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70540
BibTeX
@article{Sharaf2026,
author = {Sharaf, Hossam and Wadie, Moheb and Mansour, Noha O and Shams, Mohamed E E},
title = {Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF )},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70540}
}
EUVIMED